CN104013677A

CN104013677A - Liquid medicine for preventing and treating allergic rhinitis and wet tissue or tissue prepared by applying liquid medicine

Info

Publication number: CN104013677A
Application number: CN201410281388.7A
Authority: CN
Inventors: 张大威; 沈嘉
Original assignee: Individual
Current assignee: Individual
Priority date: 2014-06-23
Filing date: 2014-06-23
Publication date: 2014-09-03
Anticipated expiration: 2034-06-23
Also published as: CN104013677B

Abstract

The invention relates to the technical field of medicine application, and particularly relates to a liquid medicine for preventing and treating allergic rhinitis and wet tissue or tissue prepared by applying the liquid medicine. The liquid medicine is prepared from the following raw materials in parts by weight: 10-90 parts of magnolia flower, 5-40 parts of centipeda minima and 5-40 parts of cocklebur fruit. The wet tissue and tissue for preventing and treating allergic rhinitis by applying the liquid medicine are prepared from natural skin-friendly non-irritative materials, comprise a plurality of traditional Chinese medicinal effective components with the effects of resisting rhinitis and restoring nasal cavity, and are used for preventing and relieving discomfort of the nose of a patient with allergic rhinitis in daily life and non-invasively cleaning snot and other excretions when rhinitis attacks. Traditional Chinese medicine is developed to the tissue mode which is concise and convenient, the tissue has good application value and market prospect, is advantageous to popularize modern application of traditional Chinese medicines, and is beneficial to pain relieving of patients with allergic rhinitis.

Description

For preventing and treating the medicinal liquid of allergic rhinitis and applying its wet tissue of preparing or napkin

Technical field

The present invention relates to medicinal application technical field, be specifically related to for preventing and treating the medicinal liquid of allergic rhinitis and applying its wet tissue of preparing or napkin.

Background technology

Rhinitis is a kind of commonly encountered diseases, frequently-occurring disease, and age of onset at present trend becomes younger.Rhinitis refers to that inflammation appears in nasal membrane; show as hyperemia or edema; patient often there will be nasal obstruction; stream clear water tears, rhinocnesmus, throat is uncomfortable; the symptoms such as cough; Epidemiological study shows, its prevalence is greatly about 15% left and right, and the headache bringing, nasal obstruction, sneeze are having a strong impact on patient's quality of life.Rhinitis is the most common with chronic rhinitis and allergic rhinitis (also claiming allergic rhinitis).Although the clinical symptoms of rhinitis morbidity is different, very harmful, it is serious is perplexing patient, very large to patient's study, work influence.Because nose is adjacent with ear, eye and cerebral nerve maincenter, rhinitis can cause whole respiratory system, cerebral nervous system pathological changes.

Allergic rhinitis is allergic rhinitis, refers to that the medium (being mainly histamine) mainly being mediated by IgE after atopic individuals contact allergen discharges, and the non-infectious inflammatory diseases of nasal mucosa that has panimmunity competent cell and cytokine etc. to participate in.According to correlation study research, show, existing China Allergic Rhinitis surpasses 100,000,000.Classical symptom is mainly paroxysmal sneeze, clear water sample nasal mucus, nasal obstruction and rhinocnesmus.Part is with hyposmia.Although the clinical symptoms of rhinitis morbidity is different, very harmful, it is serious is perplexing patient, very large to patient's study, work influence.

At present doctor trained in Western medicine is clinical, for the treatment of allergic rhinitis, mainly contains following several method:

1. avoid contacting allergen: avoid the former stimulation of patient's contact allergy, this method is simple, but in actual life, the anaphylactogen such as dust mite cannot be avoided completely, adds that haze etc. is seriously polluted, and patient's normal work and life are produced to larger impact.

drug therapy:be current main Therapeutic Method, mainly comprise antihistamine drug, glucocorticoid medicine, Decongestant, cholilytic drug, mastocyte membrane stabilizer, LTRA, anti-IgE Mab medicine etc.For current main administering mode, be summarized as follows:

(1) oral drugs: conventional endo-medicine has the function of maintenance nasal mucosa tissue, can control the symptom of rhinitis very soon, as antihistamine drug treatment, are mainly because treating to the protopathy of rhinitis.Because oral drugs need to be absorbed with the conveying of blood and could be produced curative effect by human gastrointestinal tract, the control relief of symptoms that great majority can only be temporary transient, can not play the effect of elimination, and has more side effect.

(2) intranasal spray: the spray that contains sodium cromoglicate is only effective to the prevention of allergic rhinitis, but poor for patient's effect of completed stroke; Sympathomimetic nerve preparation is only effective to the alleviation of nasal obstruction symptom, cannot thoroughly effect a radical cure inflammation: containing the preparation of steroid patients in remission at short notice, but life-time service side effect is large, easily causes medicamentous rhinitis.

(3) local Collunarium medicine: Collunarium medicine is generally mainly used to alleviate the symptom of rhinitis.These class methods relate to some medical equipments or special-purpose article, and it is very inconvenient to use.

3. immunotherapy: indication is mainly used in the patient that routine medication is invalid.Clinical and immunologic tolerance has been induced in immunization therapy, has long-term effect, development that can prevention of allergic diseases.The conventional subcutaneous injection of allergen specific immunization therapy and sublingual administration.Be divided into cumulative stage of dosage and dosage maintenance stage the course for the treatment of, be no less than 2 years total course for the treatment of.Should adopt standardization allergen vaccine.

4. operative treatment: to part have a stuffy nose serious symptom, curative effect of medication unconspicuous perennially (persistence) rhinitis patient, can adopt operative treatment, comprise: medicine cautery, electrocautery, laser surgery etc.Because operative treatment can not directly change rhinitis patient's immune state, thereby more as auxiliary treatment means.But operative therapy to patient cause damage and misery larger, easily produce side effect in various degree, its medical expense cost is also higher.

In sum, the western medicine of allergic rhinitis is mainly for the symptomatic treatment of nasal obstruction, exists many side effect, still lacks desirable Therapeutic Method.Long and the impure meeting of anaphylactogen of disallergization treatment cycle causes anaphylactic shock; Laser therapy may be destroyed patient's nasal mucosa; During Drug therapy allergic rhinitis, Loratadine can cause the side effect such as drowsiness, sleepy and maincenter inhibition; Cortex alcohols medicine can cause endocrine regulation, femur head necrosis, amyotrophy; Decongestant is cautious use of in hypertension and adds patients with coronary heart disease; Film protectant onset time, after 1 week, belongs to preventive medicine.Visible, these limitations restrict of above various therapies they in clinical extensive use.Therefore, be necessary to seek a kind of evident in efficacy and treatment of allergic rhinitis method that untoward reaction is little, and there is advantage and unique value safely and effectively according to the medicine of the theoretical development of Chinese medicine and pharmacy.

Chinese medicine rhinitis has treating both the principal and secondary aspects of a disease, evident in efficacy, the features such as side effect of avoiding Western medicine.The Chinese patent medicine for the treatment of rhinitis mainly contains QIANBAI BIYAN PIAN, HUODAN WAN, pungent Siberian cocklebur granule etc. at present, but still can not meet patient's medication needs.Some preparation is directly used as medicine with crude drug powder without extracting, and is difficult to effectively be absorbed by the body; In some preparation, the adjuvant content such as starch or sucrose is higher, and active constituent content is lower, effect slowly, unsatisfactory curative effect.Therefore be necessary to research and develop a kind of for preventing and treating the medicinal liquid of allergic rhinitis.And current existing wet tissue and napkin are all generally pure clean purposes, function singleness, is mainly used to clean people's face, hands and article, does not still possess therapeutical effect, especially for preventing and treating the like products such as the wet tissue of allergic rhinitis or napkin.

Summary of the invention

In order to overcome the shortcoming and defect existing in prior art; the object of the present invention is to provide a kind of for preventing and treating the medicinal liquid of allergic rhinitis; this medicinal liquid can absorb by contact skin and nasal membrane, thereby plays the effect of preventing and alleviating allergic rhinitis outbreak, chronic conditioning, protection nasal membrane.

Another object of the present invention is to provide a kind of for preventing and treating wet tissue of allergic rhinitis and preparation method thereof; this wet tissue can clean nose and facial in; the Chinese medicine extraction liquid containing in wet tissue and volatile ingredient can absorb by contact skin and nasal membrane; thereby the effect that plays prevention and the outbreak of alleviation allergic rhinitis, chronic conditioning, protection nasal membrane is the good succedaneum of Allergic Rhinitis and normal person's routine use wet tissue.This preparation method step is simple, convenient operation and control.

Another object of the present invention is to provide a kind of for preventing and treating napkin of allergic rhinitis and preparation method thereof; this napkin can clean nose and facial in; the Chinese medicine volatile ingredient containing in napkin can absorb by contact skin and nasal membrane; thereby the effect that plays prevention and the outbreak of alleviation allergic rhinitis, chronic conditioning, protection nasal membrane is the good succedaneum of Allergic Rhinitis and normal person's routine use napkin.This preparation method step is simple, convenient operation and control.

Object of the present invention is achieved through the following technical solutions: for preventing and treating the medicinal liquid of allergic rhinitis, described medicinal liquid comprises the raw material of following weight portion: Flos Magnoliae 10-90 part, Herba Centipedae 5-40 part and Fructus Xanthii 5-40 part.

Flos Magnoliae is the dry flower of Magnoliacea plant Flos Magnoliae, Magnolia denudata and Flos Magnoliae, and acrid in the mouth warm in nature is returned lung stomach two warps, has the effect of dispersing wind and cold, clearing the nasal passage, is used for the treatment of headche due to wind-cold, nasal obstruction nasal mucus, turbid nasal discharge.The current clinical practice of Flos Magnoliae is mainly treatment acute and chronic rhinitis, the rhinitis symptom of allergic rhinitis and other, it evident in efficacy, effect is clear and definite, its active ingredient is volatile oil, has pharmacologically active widely, has good antiinflammatory, antiallergic, mastocyte membrane stabilizing action.In recent years the pharmacological research of Flos Magnoliae is shown, Flos Magnoliae has antihistaminic and improves microcirculatory effect, it is not in the situation that affecting blood vessels caliber, blood flow rate is obviously accelerated, to strengthen blood fortune, accelerate the removing of metabolism, thereby reach therapeutic purposes, a kind of desirable treatment of rhinitis medication at present, comprehensive rhinitis, chronic rhinitis, allergic rhinitis, hypertrophic rhinitis, sinusitis and the nasal sinusitis etc. of being used for the treatment of.

Herba Centipedae is the dry herb of feverfew Herba Centipedae, and acrid in the mouth warm in nature, returns lung meridian, has the effect of dispersing wind-cold, clearing the nasal passage and cough-relieving.The clinical headche due to wind-cold that is mainly used in, cough with copious phlegm, has a stuffy nose obstructed, nasal sinusitis watery nasal discharge.The main component of Herba Centipedae is volatile oil, sterols, flavonoid, triterpenoid compound etc., has good antiallergic, antiinflammatory and bacteriostasis.Among the people, be usually used in treating the nasopharynx laryngeal diseases such as pertussis, acute and chronic rhinitis, hypertrophic rhinitis and allergic rhinitis.The powder of Herba Centipedae, soak with ethanol liquid are used for the treatment of Allergic Rhinitis clinically, obtain good result.Modern pharmacological research shows, centipeda volatile oil has definite curative effect to allergic rhinitis, and separated flavonoid, the sesquiterpenoid obtaining can suppress the release of histamine from mastocyte from Herba Centipedae.Herba Centipedae water extraction liquid has remarkable inhibitory action to the passive skin hypersensitivity of rat and abdominal cavity mastocyte histamine release.Centipeda volatile oil is to significantly suppressing the generation of eosinophil and mastocyte in the treatment of Cavia porcellus allergic rhinitis, and the pathology that alleviate nasal mucosa change.In addition, the pseudo-guaianolide of Herba Centipedae ingredient also has the effect of anti-aurococcus, mycobacterium, bacillus subtilis.

Fructus Xanthii is the fruit of the drying and ripening band involucre of feverfew Herba Xanthii, returns lung meridian, has the effect of loose wind dehumidifying and clearing the nasal passage.Clinical being mainly used in for headche due to wind-cold, nasal obstruction watery nasal discharge, allergic rhinitis, nasal sinusitis, rubella pruritus, arthralgia chiefly caused by damp pathogen contracture.The main component volatile oil of Fructus Xanthii, sesquiterpene lactones, fatty wet goods.Modern pharmacological research shows, Fructus Xanthii extract directly acts on nasal cavity mucosa and nasal sinuses, has stronger infection, anti-allergic effects, expands small artery simultaneously, improves blood circulation.Fructus Xanthii can recover that nasal mucosa is incubated normally, moistening, filtration, barrier action.In addition, after the effect of Fructus Xanthii effective ingredient, nasal mucosa, concha nasalis inferior congestion and edema disappear, and nasal obstruction disappears thereupon.Its anti-infective pharmacological action mainly contains resisting pathogenic microbes effect and anti-inflammatory and analgesic effect.Fructus Xanthii 70% ethanol extraction suppresses the passive cutaneous anaphylaxis inflammatory reaction of the same race of people Mus to rat oral gavage, reduces mouse allelgic body gram mortality rate.Fructus Xanthii decocting liquid gavage can obviously suppress the formation of mice hemolysis plaque, macrophage phagocytic function and leukocyte and move, and shows that Fructus Xanthii all has inhibitory action to cellular immunization and humoral immunization.

Medicinal liquid of the present invention adopts Flos Magnoliae, Herba Centipedae and Fructus Xanthii to use with 10-90:5-40:5-40 weight ratio compatibility; can absorb by contact skin and nasal membrane, thereby play the effect of preventing and alleviating allergic rhinitis outbreak, chronic conditioning, protection nasal membrane.

Preferably, described medicinal liquid also comprises the extracting solution of Radix Stephaniae Tetrandrae 5-30 part, Fructus Kochiae 5-30 part, Flos Chrysanthemi Indici 5-30 part and Rhizoma Chuanxiong 5-30 part.

Radix Stephaniae Tetrandrae is the dry root of menispermaceous plants Radix stephaniae tetrandrae, bitter, cold, returns bladder, spleen channel.The effect with inducing diuresis to remove edema and wind-expelling pain-stopping.Be usually used in clinically rheumatic arthralgia, edema beriberi, dysuria, eczema sore.The chemical composition of Radix Stephaniae Tetrandrae is mainly Tetrandrine (retrandrine), demethyltetrandrine, Cyclanoline etc. multiple alkaloid and flavonoid glycoside, organic acid, volatilization wet goods.Modern pharmacological research discovery, Radix Stephaniae Tetrandrae has inhibitory action to immunity, and has extensive anti-allergic effects.It represents that composition tetrandrine has anti-allergic effects widely, is the antagonist of Anaphylactic mediator, is also the blocker of Anaphylactic mediator.In addition, Radix Stephaniae Tetrandrae also has good analgesia, antiinflammation.

The Fructus Kochiae is the dry mature fruit of chenopod Fructus Kochiae, has the effect of clearing away heat-damp and promoting diuresis and dispelling wind for relieving itching, cures mainly difficulty and pain in micturition, rubella, eczema, skin pruritus.Fructus Kochiae energy dispelling wind for relieving itching, clearing away heat and cooling blood, invigorating spleen to remove dampness.Fructus Kochiae main component is triterpene saponin and steroid etc., also contains fatty oil, alkaloid, flavone etc.Modern pharmacological research finds that it has better immunoregulation effect.Fructus Kochiae water extract can suppress monokaryon-huge phagocytic function and delayed hypersensitivity of biting system.The Fructus Kochiae 70% alcohol extract, by stablizing mast cell membrane, reduces the release of the irritated mediators such as model mice histamine, 5-hydroxy tryptamine, and anaphylactic type and delayed allergy are had to inhibitory action.In addition, the Fructus Kochiae also has the effects such as good antiinflammatory, antibacterial, antipruritic.

Flos Chrysanthemi Indici is the dry capitulum of feverfew Herba Dendranthematis indici, has the effect of heat-clearing and toxic substances removing and detumescence.On tcm clinical practice, be used for the treatment of furuncle carbuncle, conjunctival congestion and swelling pain, headache dizzy.Flos Chrysanthemi Indici mainly contains the chemical compositions such as flavonoid, terpenoid, volatile oil, organic acid and polysaccharide, has anti-mattress antiinflammatory, and antiviral regulates immunity of organisms, the pharmacological actions such as antagonism various acute inflammation, chronic inflammatory disease and immune inflammation reaction; Be mainly used in clinically at present the diseases such as preventing cold, upper respiratory tract infection, epidemic cerebrospinal meningitis.Flos Chrysanthemi Indici can be widely used in treatment furuncle carbuncle, laryngopharynx swelling and pain, wind-fire acute conjunctivitis, the disease such as dizzy of having a headache.

Rhizoma Chuanxiong is the dry rhizome of samphire Rhizoma Chuanxiong, has the effect of blood-activating and qi-promoting and wind-expelling pain-stopping.The position of Rhizoma Chuanxiong effect is very extensive, and forefathers just say its up head, the descending sea of blood, and middle relieving stagnation, side reaches extremity, and the every aspect of whole body can be used.Wind-expelling pain-stopping, especially treats the most important medicine of wind syndrome of head, and all headaches must be by the saying of Rhizoma Chuanxiong.Modern study, the effective pain relieving composition of Rhizoma Chuanxiong (comprising volatile oil or alkaloid) is easy to see through brain-alveolar-capillary barrier, in head generation curative effect.Due to wind and cold, wind heat, rheumatism, blood deficiency, blood stasis, have a headache and can use with card compatibility, also can be used for the various gynecological diseases such as blood stasis amenorrhea, dysmenorrhea.Wind-expelling pain-stopping, effectiveness is excellent, can control the diseases such as wind syndrome of head headache, rheumatic arthralgia.Modern pharmacology proof Rhizoma Chuanxiong has good sedation to central nervous system, can also antibacterial blood pressure lowering, large intestine, typhoid fever, Salmonella paratyphi and vibrio cholera etc. are had to inhibitory action.

Medicinal liquid of the present invention is by effective compatibility of Flos Magnoliae, Herba Centipedae and Fructus Xanthii and Radix Stephaniae Tetrandrae, the Fructus Kochiae, Flos Chrysanthemi Indici and Rhizoma Chuanxiong, and strictly to control its weight ratio be 10-90:5-40:5-40:5-30:5-30:5-30:5-30, not only for allergic rhinitis, also the nose malaise symptoms such as the caused various nasal obstructions of acute rhinitis, chronic rhinitis, sinusitis and Common Cold, rhinocnesmus, sneeze, rhinorrhea are had to the effects such as prevention, alleviation and treatment.

Preferably, described medicinal liquid comprises the extracting solution of the raw material of following weight portion: the extracting solution of Flos Magnoliae 20-80 part, Herba Centipedae 10-40 part and Fructus Xanthii 10-40 part, Radix Stephaniae Tetrandrae 5-25 part, Fructus Kochiae 5-25 part, Flos Chrysanthemi Indici 5-25 part and Rhizoma Chuanxiong 5-30 part.

More preferred, described medicinal liquid comprises the extracting solution of the raw material of following weight portion: the extracting solution of Flos Magnoliae 30-70 part, Herba Centipedae 15-35 part and Fructus Xanthii 15-35 part, Radix Stephaniae Tetrandrae 5-20 part, Fructus Kochiae 5-20 part, Flos Chrysanthemi Indici 5-20 part and Rhizoma Chuanxiong 10-30 part.

More preferred, described medicinal liquid comprises the extracting solution of the raw material of following weight portion: the extracting solution of Flos Magnoliae 40-60 part, Herba Centipedae 20-30 part and Fructus Xanthii 20-30 part, Radix Stephaniae Tetrandrae 5-15 part, Fructus Kochiae 5-15 part, Flos Chrysanthemi Indici 5-15 part and Rhizoma Chuanxiong 15-25 part.

More preferred, described medicinal liquid comprises the extracting solution of the raw material of following weight portion: the extracting solution that 50 parts of Flos Magnoliaes, 25 parts of Herba Centipedae and 25 parts of Fructus Xanthii, 10 parts of Radixs Stephaniae Tetrandrae, 10 parts of the Fructus Kochiae, 10 parts of Flos Chrysanthemi Indicis and Rhizoma Chuanxiong are 20 parts.

Another is preferred, and described medicinal liquid comprises the extracting solution of the raw material of following weight portion: the extracting solution of Flos Magnoliae 10-50 part, Herba Centipedae 5-25 part and Fructus Xanthii 5-25 part, Radix Stephaniae Tetrandrae 5-15 part, Fructus Kochiae 5-15 part, Flos Chrysanthemi Indici 5-15 part and Rhizoma Chuanxiong 5-20 part.

More preferred, described medicinal liquid comprises the extracting solution of the raw material of following weight portion: the extracting solution that 30 parts of Flos Magnoliaes, 15 parts of Herba Centipedae and 15 parts of Fructus Xanthii, 10 parts of Radixs Stephaniae Tetrandrae, 10 parts of the Fructus Kochiae, 10 parts of Flos Chrysanthemi Indicis and Rhizoma Chuanxiong are 12 parts.

Another is preferred, and described medicinal liquid comprises the extracting solution of the raw material of following weight portion: the extracting solution of Flos Magnoliae 50-90 part, Herba Centipedae 25-40 part and Fructus Xanthii 25-40 part, Radix Stephaniae Tetrandrae 15-30 part, Fructus Kochiae 15-30 part, Flos Chrysanthemi Indici 15-30 part and Rhizoma Chuanxiong 20-30 part.

More preferred, described medicinal liquid comprises the extracting solution of the raw material of following weight portion: the extracting solution that 70 parts of Flos Magnoliaes, 32 parts of Herba Centipedae and 32 parts of Fructus Xanthii, 22 parts of Radixs Stephaniae Tetrandrae, 22 parts of the Fructus Kochiae, 22 parts of Flos Chrysanthemi Indicis and Rhizoma Chuanxiong are 25 parts.

Compare with currently available technology, the innovation of this patent is embodied in composition and the compatibility of Chinese medicine, in for allergic rhinitis cardinal symptom, on ingredients, also considered the clinical manifestation of nose sensitive patients, select the problems such as corresponding medicine is alleviated common headache, shed tears, pruritus, thereby played a comprehensive prevention and mitigation.On ingredients, select Flos Magnoliae, Herba Centipedae, Fructus Xanthii for the cardinal symptom of rhinitis, nose sensitivity, the curative effect that adds the Radix Stephaniae Tetrandrae reinforcement principal agent with extensive anti-allergic effects, compatibility Rhizoma Chuanxiong is alleviated the headache of nose sensitive patients and is promoted Drug Percutaneous Absorption simultaneously, compatibility has Flos Chrysanthemi Indici alleviation headache and the symptom of the many tears of conjunctival congestion, in addition the compatibility Fructus Kochiae dispelling wind for relieving itching of antipyretic and antidote functions.

Preferably, described medicinal liquid also comprises the extracting solution of Flos Camelliae Japonicae 5-15 part, Cortex toonae sinensis radicis 10-20 part, Bai Mang 4-12 part and Flos Impatientis 10-18 part.

Preferably, described medicinal liquid also comprises the extracting solution of Flos Camelliae Japonicae 8-12 part, Cortex toonae sinensis radicis 12-18 part, Bai Mang 6-10 part and Flos Impatientis 12-16 part.

More preferred, described medicinal liquid also comprises the extracting solution of 14 parts of 10 parts of Flos Camelliae Japonicae, 14 parts of Cortex toonae sinensis radicis, 8 parts of Bai Mang and Flos Impatientiss.

Flos Camelliae Japonicae has the effect of cooling blood for hemostasis and dissipating blood stasis for subsidence of swelling; Cortex toonae sinensis radicis has heat clearing and damp drying and the antipruritic effect of hemostasis; Bai Mang has the effect of clearing heat for detumescence; Flos Impatientis has the effect of expelling wind and removing dampness and promoting blood circulation and stopping pain.

Medicinal liquid of the present invention is by effective compatibility of Flos Magnoliae, Herba Centipedae and Fructus Xanthii and Radix Stephaniae Tetrandrae, the Fructus Kochiae, Flos Chrysanthemi Indici and Rhizoma Chuanxiong and Flos Camelliae Japonicae, Cortex toonae sinensis radicis, Bai Mang and Flos Impatientis; and strictly to control its weight ratio be 10-90:5-40:5-40:5-30:5-30:5-30:5-30:5-15:10-20:6-12:12-1 8; have that wind dispelling is had one's ideas straightened out, the effect of refreshment; and most Allergic Rhinitis are had to the effect of remission, can be used for the alleviation of allergic rhinitis symptom, generation and the daily nursing etc. again of Polyglucan rhinitis.

Another object of the present invention is achieved through the following technical solutions: a kind of apply that medicinal liquid described above makes for preventing and treating the wet tissue of allergic rhinitis, described wet tissue comprises carrier material and described medicinal liquid.

Preferably, described carrier material is non-woven fabrics; Described medicinal liquid also comprises additive A 1-2 part, and described additive A comprises in surfactant, osmotic pressure regulator, wetting agent, Percutaneous absorption enhancer, pH adjusting agent, cosolvent, suspending agent, antioxidant and antibacterial obtain at least one.

More preferred, described additive A comprises osmotic pressure regulator, wetting agent, Percutaneous absorption enhancer, pH adjusting agent, cosolvent, antioxidant and antibacterial; Described additive A also comprises at least one in surfactant and suspending agent.That is: described additive A comprises osmotic pressure regulator, wetting agent, Percutaneous absorption enhancer, pH adjusting agent, cosolvent, antioxidant and antibacterial; Or described additive A comprises surfactant, osmotic pressure regulator, wetting agent, Percutaneous absorption enhancer, pH adjusting agent, cosolvent, antioxidant and antibacterial; Or described additive A comprises osmotic pressure regulator, wetting agent, Percutaneous absorption enhancer, pH adjusting agent, cosolvent, suspending agent, antioxidant and antibacterial.Or described additive A comprises surfactant, osmotic pressure regulator, wetting agent, Percutaneous absorption enhancer, pH adjusting agent, cosolvent, suspending agent, antioxidant and antibacterial.

Described surfactant is at least one in tween, span, lecithin, dodecylbenzene sodium sulfonate, Myrij, Brij, poloxamer, polyoxyethylene hydrogenated Oleum Ricini, sucrose fatty acid ester, sodium lauryl sulphate, hexadecanol sodium sulfate, dihexyl sodium sulfosuccinate, sodium glycocholate, Fel Bovis seu Bubali sodium sulfonate and benzyl chloride methyl ethylamine.Preferably, described surfactant is at least one in polyoxyethylene hydrogenated Oleum Ricini, sucrose fatty acid ester, sodium lauryl sulphate, Fel Bovis seu Bubali sodium sulfonate and benzyl chloride methyl ethylamine.The mixture more preferred, described surfactant is comprised of with weight ratio 1:2-3:1.5-2.5 Fel Bovis seu Bubali sodium sulfonate, benzyl chloride methyl ethylamine and polyoxyethylene hydrogenated Oleum Ricini.When adopting, Fel Bovis seu Bubali sodium sulfonate, benzyl chloride methyl ethylamine and polyoxyethylene hydrogenated Oleum Ricini are composite as surfactant, and to control its weight ratio be 1:2-3:1.5-2.5, can make wet tissue system stable homogeneous.

Described osmotic pressure regulator is at least one in sodium chloride, potassium chloride, sodium acetate, glycerol, glucose, propylene glycol and mannitol.Preferably, described osmotic pressure regulator is sodium chloride and/or glucose.The mixture more preferred, described osmotic pressure regulator is comprised of with weight ratio 2-4:1 sodium chloride and glucose.When adopting sodium chloride and glucose as osmotic pressure regulator, and to control its weight ratio be 2-4:1, can make the osmotic pressure of medicinal liquid slightly high or equal nasal cavity liquid, reduces the zest of medicinal liquid.

The osmotic pressure of medicinal liquid of the present invention is equivalent to 0.8%-1.2% sodium chloride concentration, is preferably 0.9-1.1% sodium chloride concentration, selects suitable osmotic pressure regulator can make the osmotic pressure of medicinal liquid slightly high or equal nasal cavity liquid, reduces the zest of medicinal liquid.

Described wetting agent is at least one in glycerol, propylene glycol, liquid Paraffin, sorbitol and hyaluronic acid.Preferably, described wetting agent is at least one in liquid Paraffin, sorbitol and hyaluronic acid.The mixture more preferred, described wetting agent is comprised of with weight ratio 1.2-1.8:1:1.4-2.2 liquid paraffin, hyaluronic acid and sorbitol.When adopting, liquid paraffin, hyaluronic acid and sorbitol are composite as wetting agent, and to control its weight ratio be 1:2-3:1.5-2.5, can improve the skin effect of wet tissue.

Described Percutaneous absorption enhancer is at least one in dimethyl sulfoxide, azone, propylene glycol, glycerol, Polyethylene Glycol, carbamide, Oleum menthae and Oleum Terebinthinae.Preferably, described Percutaneous absorption enhancer is at least one in azone, propylene glycol, Oleum menthae and Oleum Terebinthinae.The mixture more preferred, described Percutaneous absorption enhancer is comprised of with weight ratio 1.2-1.8:1 azone and Oleum menthae.When adopting azone and Oleum menthae as Percutaneous absorption enhancer and to control its weight ratio be 1.2-1.8:1, can make wet tissue character before the deadline keep stable.

Described pH adjusting agent is at least one in boric acid, Borax, sodium hydrogen phosphate, sodium dihydrogen phosphate, potassium dihydrogen phosphate, dipotassium hydrogen phosphate, sodium carbonate, sodium bicarbonate, potassium carbonate, potassium bicarbonate, acetic acid, sodium acetate, citric acid, sodium citrate, tartaric acid, sodium tartrate, sodium hydroxide, potassium hydroxide, hydrochloric acid and phosphoric acid.Be preferably, described pH adjusting agent is at least one in boric acid, Borax, sodium hydrogen phosphate, sodium dihydrogen phosphate, potassium dihydrogen phosphate and dipotassium hydrogen phosphate.The mixture more preferred, described pH adjusting agent is comprised of with weight ratio 1:0.8-1.2 sodium hydrogen phosphate and sodium dihydrogen phosphate.When adopting, sodium hydrogen phosphate and sodium dihydrogen phosphate are composite as pH adjusting agent, and to control its weight ratio be 1:0.8-1.2, can make the pH value of medicinal liquid and nasal cavity liquid approach, the zest of minimizing medicinal liquid.

The pH value of medicinal liquid of the present invention is 5.5-7.5, and preferred, the pH value of described medicinal liquid is 6-7, more preferred, and the pH value of described medicinal liquid is 6.5.During due to nasal cavity allergy or inflammation, be alkalescence, easily make bacterial multiplication and affect normal ciliary movement, therefore, the pH value of medicinal liquid of the present invention should be controlled at 5.5-7.5.

Described cosolvent is ethanol, glycerol, propylene glycol, Liquid Macrogol or PEG400.Preferably, the mixture that described cosolvent is comprised of with weight ratio 1.4-1.8:1 glycerol and propylene glycol.When adopting, glycerol and propylene glycol are composite as cosolvent, and to control its weight ratio be 1.4-1.8:1, have the effect of moisturizing concurrently, can increase effective ingredient dissolubility, make wet tissue character before the deadline keep stable.

Described suspending agent is at least one in arabic gum, tragakanta, polyvinylpyrrolidone, methylcellulose and hydroxy methocel.Preferably, described suspending agent is polyvinylpyrrolidone and/or hydroxy methocel.The mixture more preferred, described suspending agent is comprised of with weight ratio 1:1.5-2.5 polyvinylpyrrolidone and hydroxy methocel.When adopting, polyvinylpyrrolidone and hydroxy methocel are composite as suspending agent, and to control its weight ratio be 1:1.5-2.5, can make wet tissue character before the deadline keep stable.

Described antioxidant is at least one in Yoshinox BHT, Butylated hydroxyanisole, butylated hydroxyanisol, ethanolamine, diethanolamine, triethanolamine, cholesterol, cholesteryl ester, sodium sulfite, sodium sulfite, sodium pyrosulfite, sodium nitrite, sodium thiosulfate, ascorbic acid, ascorbyl stearate, cysteine, tocopherol acetas, disodiumedetate and calcio-disodium edetate.Preferably, described antioxidant is at least one in sodium sulfite, sodium pyrosulfite and ascorbic acid.The mixture more preferred, described antioxidant is comprised of with weight ratio 2-3:1 sodium sulfite and ascorbic acid.When adopting, sodium sulfite and ascorbic acid are composite as antioxidant, and to control its weight ratio be 2-3:1, can make wet tissue character before the deadline keep stable.

Described antibacterial is methyl parahydroxybenzoate, ethylparaben, propyl p-hydroxybenzoate, butyl p-hydroxybenzoate, benzyl alcohol, chlorobutanol, Oleum menthae, Oleum Asari, KF88, iodo propinyl butyl carbamate, chitosan, nanometer silver, ethyl hydroxybenzoate, chlorhexidine gluconate, Chlorhexidine hydrochloride, chlorhexidine acetate, poly hexamethylene biguanide, polyhexamethylene guanidine, cetrimonium bromide, benzalkonium chloride, Bian rope chloramines, at least one in benzalkonium bromide and phenoxyethanol.Preferably, described antibacterial is at least one in methyl parahydroxybenzoate, ethylparaben, propyl p-hydroxybenzoate, butyl p-hydroxybenzoate, benzyl alcohol, chlorobutanol, Oleum menthae and Oleum Asari.The mixture more preferred, described antibacterial is comprised of with weight ratio 0.4-0.8:1.2-1.6:1 ethylparaben, chlorobutanol and Oleum Asari.When adopting, ethylparaben, chlorobutanol and Oleum Asari are composite as antibacterial, and to control its weight ratio be 0.4-0.8:1.2-1.6:1, can play good fungistatic effect, and the microbial limit of wet tissue is met the requirements.

For preventing and treating a preparation method for the wet tissue of allergic rhinitis, comprise the steps:

(1) according to the weight proportion of raw material, take medical material, pulverize or grind, extract by concentrated or dilution, add described additive A, obtain medicinal liquid;

(2) described non-woven fabrics be impregnated in above-mentioned medicinal liquid, obtain described for preventing and treating the wet tissue of allergic rhinitis.

In described step (1), extract and comprise super critical extraction, vapor distillation extraction method, reflux extraction or decoct extraction method; Extraction water is municipal tap water, distilled water, purified water, sterilized water, deionized water or water for injection.

The concrete steps of described super critical extraction are: the weight proportion according to raw material takes medical material, clean and take out impurity, be ground into the powder of particle diameter < 1mm, use supercritical carbon dioxide extraction apparatus carbon dioxide abstraction quintessence oil, extraction conditions is: extracting pressure 20MPa, 40 ℃ of extraction temperature, extraction time 60min, gained quintessence oil dissolve with ethanol, adds described additive A after dilute with water, obtain medicinal liquid;

The concrete steps of described vapor distillation extraction method are: the weight proportion according to raw material takes medical material, clean and take out impurity, are ground into graininess, with extraction by steam distillation volatile oil, by adding described additive A after volatile oil dilution, obtain medicinal liquid;

The concrete steps of described reflux extraction are: the weight proportion according to raw material takes medical material, clean and take out impurity, are ground into powder, with 8-15, doubly measure 50-95% alcohol reflux 2 times, each 1.5-2h, extracting solution is concentrated, in concentrated solution, add described additive A, obtain medicinal liquid;

The concrete steps of described decoction extraction method are: the weight proportion according to raw material takes medical material, clean and take out impurity, be ground into powder, with 8-15, doubly measure distilled water immersion 0.5-1h, heating decocts 3 times, and each 1.5-2h is concentrated by extracting solution, in concentrated solution, add described additive A, obtain medicinal liquid;

Described step (2) is specially: described non-woven fabrics be impregnated in above-mentioned medicinal liquid, through sterilizing, cutting, folding, rubberizing, pack and sealing, obtain described for preventing and treating the wet tissue of allergic rhinitis.

A kind of for the wet tissue of preventing and treating allergic rhinitis for the preparation of the application that prevents and treats allergic rhinitis and related indication medical material, wet tissue of the present invention, not only for allergic rhinitis, also has the effects such as prevention, alleviation and treatment to nose related symptoms such as the caused various nasal obstructions of acute rhinitis, chronic rhinitis, sinusitis and Common Cold, rhinocnesmus, sneeze, rhinorrhea.

Wet tissue of the present invention can clean nose and facial in; the Chinese medicine extraction liquid containing in wet tissue and volatile ingredient can absorb by contact skin and nasal membrane; thereby the effect that plays prevention and the outbreak of alleviation allergic rhinitis, chronic conditioning, protection nasal membrane is the good succedaneum of Allergic Rhinitis and normal person's routine use wet tissue.

Another object of the present invention is achieved through the following technical solutions: a kind of apply that medicinal liquid described above makes for preventing and treating the napkin of allergic rhinitis, described napkin comprises carrier material and described medicinal liquid.

Preferably, described carrier material is fibrous paper or paper oleo stock; Described medicinal liquid also comprises additive B 1-2 part, and described additive B comprises at least one in viscosity modifier, Percutaneous absorption enhancer, pH adjusting agent, cosolvent, suspending agent, antioxidant and antibacterial.

More preferred, described additive B comprises Percutaneous absorption enhancer, pH adjusting agent, cosolvent, antioxidant and antibacterial; Described additive B also comprises at least one in viscosity modifier and suspending agent.That is, described additive B comprises Percutaneous absorption enhancer, pH adjusting agent, cosolvent, antioxidant and antibacterial; Or described additive B comprises viscosity modifier, Percutaneous absorption enhancer, pH adjusting agent, cosolvent, antioxidant and antibacterial; Or described additive B comprises Percutaneous absorption enhancer, pH adjusting agent, cosolvent, suspending agent, antioxidant and antibacterial; Or described additive B comprises viscosity modifier, Percutaneous absorption enhancer, pH adjusting agent, cosolvent, suspending agent, antioxidant and antibacterial.

Described viscosity modifier is at least one in dextran, cellulose family, hyaluronic acid sodium, polyvinyl alcohol, carbomer, polyvidone, chitosan, chitosan derivatives, carboxy vinyl polymer and CP.Preferably, described viscosity modifier is at least one in dextran, hyaluronic acid sodium, polyvinyl alcohol and CP.The mixture more preferred, described viscosity modifier is comprised of with weight ratio 1:1.8-2.4:2.5-3.5 hyaluronic acid sodium, polyvinyl alcohol and CP.When adopting hyaluronic acid sodium, polyvinyl alcohol and CP as viscosity modifier, and to control its weight ratio be 1:1.8-2.4:2.5-3.5, can make medicinal liquid have certain viscosity, improves the comfortableness of napkin and in holdup time of nasal cavity.

Described Percutaneous absorption enhancer is at least one in dimethyl sulfoxide, azone, propylene glycol, glycerol, Polyethylene Glycol, carbamide, Oleum menthae and Oleum Terebinthinae.Preferably, described Percutaneous absorption enhancer is at least one in azone, propylene glycol, Oleum menthae and Oleum Terebinthinae.The mixture more preferred, described Percutaneous absorption enhancer is comprised of with weight ratio 1:1.6-2.4 azone and Oleum Terebinthinae.When adopting azone and Oleum Terebinthinae as Percutaneous absorption enhancer and to control its weight ratio be 1:1.6-2.4, can make napkin character before the deadline keep stable.

Described pH adjusting agent is at least one in boric acid, Borax, sodium hydrogen phosphate, sodium dihydrogen phosphate, potassium dihydrogen phosphate, dipotassium hydrogen phosphate, sodium carbonate, sodium bicarbonate, potassium carbonate, potassium bicarbonate, acetic acid, sodium acetate, citric acid, sodium citrate, tartaric acid, sodium tartrate, sodium hydroxide, potassium hydroxide, hydrochloric acid and phosphoric acid.Be preferably, described pH adjusting agent is at least one in boric acid, Borax, sodium hydrogen phosphate, sodium dihydrogen phosphate, potassium dihydrogen phosphate and dipotassium hydrogen phosphate.The mixture more preferred, described pH adjusting agent is comprised of with weight ratio 0.8-1.2:1 boric acid and Borax.When adopting, boric acid and Borax are composite as pH adjusting agent, and to control its weight ratio be 0.8-1.2:1, can make the pH value of medicinal liquid and nasal cavity liquid approach, the zest of minimizing medicinal liquid.

Described cosolvent is ethanol, glycerol, propylene glycol, Liquid Macrogol or PEG400.Preferably, the mixture that described cosolvent is comprised of with weight ratio 1.4-1.8:1 glycerol and propylene glycol.When adopting, glycerol and propylene glycol are composite as cosolvent, and to control its weight ratio be 1.4-1.8:1, can increase effective ingredient dissolubility, make napkin character before the deadline keep stable.

Described suspending agent is at least one in arabic gum, tragakanta, polyvinylpyrrolidone, methylcellulose and hydroxy methocel.Preferably, described suspending agent is polyvinylpyrrolidone and/or methylcellulose.The mixture more preferred, described suspending agent is comprised of with weight ratio 1:1.5-2.5 polyvinylpyrrolidone and methylcellulose.When adopting, polyvinylpyrrolidone and methylcellulose are composite as suspending agent, and to control its weight ratio be 1:1.5-2.5, can make napkin character before the deadline keep stable.

Described antioxidant is at least one in Yoshinox BHT, Butylated hydroxyanisole, butylated hydroxyanisol, ethanolamine, diethanolamine, triethanolamine, cholesterol, cholesteryl ester, sodium sulfite, sodium sulfite, sodium pyrosulfite, sodium nitrite, sodium thiosulfate, ascorbic acid, ascorbyl stearate, cysteine, tocopherol acetas, disodiumedetate and calcio-disodium edetate.Preferably, described antioxidant is at least one in sodium sulfite, sodium pyrosulfite and ascorbic acid.The mixture more preferred, described antioxidant is comprised of with weight ratio 1.2-1.8:1 sodium pyrosulfite and ascorbic acid.When adopting, sodium pyrosulfite and ascorbic acid are composite as antioxidant, and to control its weight ratio be 2-3:1, can make napkin character before the deadline keep stable.

Described antibacterial is methyl parahydroxybenzoate, ethylparaben, propyl p-hydroxybenzoate, butyl p-hydroxybenzoate, benzyl alcohol, chlorobutanol, Oleum menthae, Oleum Asari, KF88, iodo propinyl butyl carbamate, chitosan, nanometer silver, ethyl hydroxybenzoate, chlorhexidine gluconate, Chlorhexidine hydrochloride, chlorhexidine acetate, poly hexamethylene biguanide, polyhexamethylene guanidine, cetrimonium bromide, benzalkonium chloride, Bian rope chloramines, at least one in benzalkonium bromide and phenoxyethanol.Preferably, described antibacterial is at least one in methyl parahydroxybenzoate, ethylparaben, propyl p-hydroxybenzoate, butyl p-hydroxybenzoate, benzyl alcohol, chlorobutanol, Oleum menthae and Oleum Asari.The mixture more preferred, described antibacterial is comprised of with weight ratio 0.8-1.2:1.6-2.4:1 methyl parahydroxybenzoate, chlorobutanol and Oleum menthae.When adopting, methyl parahydroxybenzoate, chlorobutanol and Oleum menthae are composite as antibacterial, and to control its weight ratio be 0.4-0.8:1.2-1.6:1, can play good fungistatic effect, and the microbial limit of napkin is met the requirements.

For preventing and treating a preparation method for the napkin of allergic rhinitis, comprise the steps:

(1) according to the weight proportion of raw material, take medical material, pulverize or grind, extract by concentrated or dilution, add described additive B, obtain medicinal liquid;

(2) by above-mentioned medicine liquid spray in described fibrous paper, after oven dry, obtain described for preventing and treating the napkin of allergic rhinitis; Or, above-mentioned medicinal liquid is joined in paper oleo stock, through papermaking processing, obtain described for preventing and treating the napkin of allergic rhinitis.

In described step (1), extract and comprise super critical extraction and vapor distillation extraction method; Extraction water is municipal tap water, distilled water, purified water, sterilized water, deionized water or water for injection.

The concrete steps of described super critical extraction are: the weight proportion according to raw material takes medical material, clean and take out impurity, be ground into the powder of particle diameter < 1mm, use supercritical carbon dioxide extraction apparatus carbon dioxide abstraction quintessence oil, extraction conditions is: extracting pressure 15-25MPa, extraction temperature 35-45 ℃, extraction time 50-70min, gained quintessence oil dissolve with ethanol, adds described additive B after dilute with water, obtain medicinal liquid;

The concrete steps of described vapor distillation extraction method are: the weight proportion according to raw material takes medical material, clean and take out impurity, are ground into graininess, with extraction by steam distillation volatile oil, by adding described additive B after volatile oil dilution, obtain medicinal liquid;

In described step (2), papermaking is processed as the paper technology of this area routine, and the paper oleo stock that is added with medicinal liquid is machined for to the napkin of preventing and treating allergic rhinitis.

A kind of for the napkin of preventing and treating allergic rhinitis for the preparation of the application that prevents and treats allergic rhinitis and related indication medical material, napkin of the present invention, not only for allergic rhinitis, also has the effects such as prevention, alleviation and treatment to nose related symptoms such as the caused various nasal obstructions of acute rhinitis, chronic rhinitis, sinusitis and Common Cold, rhinocnesmus, sneeze, rhinorrhea.

Napkin of the present invention can clean nose and facial in; the Chinese medicine volatile ingredient containing in napkin can absorb by contact skin and nasal membrane; thereby the effect that plays prevention and the outbreak of alleviation allergic rhinitis, chronic conditioning, protection nasal membrane is the good succedaneum of Allergic Rhinitis and normal person's routine use napkin.

Beneficial effect of the present invention is: medicinal liquid of the present invention adopts Flos Magnoliae, and Chinese medicine Flos Magnoliae is a kind of desirable treatment of rhinitis medication at present, comprehensive rhinitis, chronic rhinitis, allergic rhinitis, hypertrophic rhinitis, sinusitis, the nasal sinusitis etc. of being used for the treatment of; Medicinal liquid of the present invention adopts Herba Centipedae, and Chinese medicine Herba Centipedae has good anti-allergic effects, antiinflammatory action and antibacterial action, remarkable for allergic rhinitis effect clinically; Medicinal liquid of the present invention adopts Fructus Xanthii, and Chinese medicine Fructus Xanthii has good anti-allergic effects, anti-inflammatory and analgesic effect and resisting pathogenic microbes effect.

Medicinal liquid of the present invention adopts Flos Magnoliae, Herba Centipedae and Fructus Xanthii to use than compatibility with specified weight, can absorb by contact skin and nasal membrane, thereby play the effect of preventing and alleviating allergic rhinitis outbreak, chronic conditioning, protection nasal membrane.

The present invention will be mixed with medicinal liquid by different proportionings to such as Herba Centipedae, Flos Magnoliae and Fructus Xanthii etc. of the medicable medicine of rhinitis tool, and medicine liquid spray or proofing are had on the wet tissue or napkin of higher-strength, pack, easy to use, tearing packing off can use.When using this wet tissue or napkin, medicine directly contacts with human body, utilizes the volatility of medicine and the breathing of human body simultaneously, medicine is delivered directly in the respiratory apparatus of human body, thereby reaches the object of preventing and treating allergic rhinitis.

Wet tissue of the present invention and napkin all adopt natural pro-skin nonirritant material, contain multiple anti-rhinitis clearing the nasal passage pharmaceutically active ingredient on, uncomfortable for prevention and the daily nose of alleviation allergic rhinitis patient, and the secretions such as rhinitis when outbreak non-invasi cleaning nasal mucus, Chinese medicine is developed to this succinctly form easily of napkin, there is good using value and market prospect, be conducive to promote the modern Application of Chinese medicine, be conducive to alleviate the misery of Allergic Rhinitis.

Wet tissue of the present invention or napkin are applied to nose, nasal cavity outside etc. close to the position of nasal cavity; have that wind dispelling is had one's ideas straightened out, the effect of refreshment; and most Allergic Rhinitis are had to the effect of remission, can be used for the alleviation of allergic rhinitis symptom, generation and the daily nursing etc. again of Polyglucan rhinitis.After wet tissue of the present invention or napkin are used, comfortable, salubrious, foreign sense that nose is felt, can alleviate allergic rhinitis related symptoms, and have no side effect, and has removed the various inconvenience that bring due to nose discomfort, is that articles for use are safeguarded in a kind of good nasal cavity health care.

Wet tissue of the present invention or napkin play the effect that prevents and treats allergic rhinitis in clean nose, have filled up the blank of existing treatment of rhinitis method; And select Chinese medicine, prescription is simple, broken through complicated, safe and effective, the toxic and side effects of having avoided Western medicine of Chinese medicine prescription; Easy to use, be easy to carry, immediately to take, the complexity of having avoided Chinese medicine to adjust is loaded down with trivial details.Wet tissue of the present invention and napkin have to be made simply, portably uses conveniently, evident in efficacy, low cost and other advantages.

the specific embodiment:

For the ease of those skilled in the art's understanding, below in conjunction with embodiment, the present invention is further illustrated, and the content that embodiment is mentioned not is limitation of the invention.

Embodiment 1

For preventing and treating the medicinal liquid of allergic rhinitis, described medicinal liquid comprises the extracting solution of the raw material of following weight portion: 5 parts of 10 parts of Flos Magnoliaes, 5 parts of Herba Centipedae and Fructus Xanthii.

For preventing and treating a wet tissue for allergic rhinitis, described wet tissue comprises carrier material and medicinal liquid described above.Wherein, described carrier material is non-woven fabrics; Described medicinal liquid also comprises 1 part of additive A, and described additive A comprises 0.55 part of 0.1 part of osmotic pressure regulator, 0.1 part of wetting agent, 0.1 part of Percutaneous absorption enhancer, 0.05 part of pH adjusting agent, 0.05 part of cosolvent, 0.05 part, antioxidant and antibacterial; Described osmotic pressure regulator is sodium chloride; Described wetting agent is liquid paraffin; Described Percutaneous absorption enhancer is dimethyl sulfoxide; Described pH adjusting agent is the mixture that described pH adjusting agent is comprised of with weight ratio 1:0.8 sodium hydrogen phosphate and sodium dihydrogen phosphate; Described cosolvent is glycerol; Described antioxidant is Yoshinox BHT; Described antibacterial is methyl parahydroxybenzoate.

(1) according to the weight proportion of raw material, take medical material, clean and take out impurity, be ground into the powder of particle diameter < 1mm, use supercritical carbon dioxide extraction apparatus carbon dioxide abstraction quintessence oil, extraction conditions is: extracting pressure 15MPa, 35 ℃ of extraction temperature, extraction time 70min, gained quintessence oil dissolve with ethanol, adds described additive A after dilute with water, obtain medicinal liquid;

(2) described non-woven fabrics be impregnated in above-mentioned medicinal liquid, through sterilizing, cutting, folding, rubberizing, pack and sealing, obtain described for preventing and treating the wet tissue of allergic rhinitis.

For preventing and treating a napkin for allergic rhinitis, described napkin comprises carrier material and medicinal liquid described above.Wherein, described carrier material is fibrous paper; Described medicinal liquid also comprises 1 part of additive B, and described additive B comprises 0.6 part of 0.1 part of Percutaneous absorption enhancer, 0.1 part of pH adjusting agent, 0.1 part of cosolvent, 0.1 part, antioxidant and antibacterial; Described Percutaneous absorption enhancer is Oleum Terebinthinae; The mixture that described pH adjusting agent is comprised of with weight ratio 0.8:1 boric acid and Borax; Described cosolvent is glycerol; Described antioxidant is Yoshinox BHT; Described antibacterial is methyl parahydroxybenzoate.

(1) according to the weight proportion of raw material, take medical material, clean and take out impurity, be ground into the powder of particle diameter < 1mm, use supercritical carbon dioxide extraction apparatus carbon dioxide abstraction quintessence oil, extraction conditions is: extracting pressure 25MPa, 45 ℃ of extraction temperature, extraction time 50min, gained quintessence oil dissolve with ethanol, adds described additive B, obtains medicinal liquid;

(2) by above-mentioned medicine liquid spray in described fibrous paper, after oven dry, obtain described for preventing and treating the napkin of allergic rhinitis.

Embodiment 2

The difference of the present embodiment and above-described embodiment 1 is: described medicinal liquid comprises the extracting solution of the raw material of following weight portion: 15 parts of 30 parts of Flos Magnoliaes, 15 parts of Herba Centipedae and Fructus Xanthii.

For preventing and treating a wet tissue for allergic rhinitis, described wet tissue comprises carrier material and medicinal liquid described above.Wherein, described carrier material is non-woven fabrics; Described medicinal liquid also comprises 1.3 parts of additive A, and described additive A comprises 0.6 part of 0.1 part of osmotic pressure regulator, 0.1 part of wetting agent, 0.2 part of Percutaneous absorption enhancer, 0.1 part of pH adjusting agent, 0.1 part of cosolvent, 0.1 part, antioxidant and antibacterial; Described osmotic pressure regulator is potassium chloride; Described wetting agent is hyaluronic acid; Described Percutaneous absorption enhancer is azone; The mixture that described pH adjusting agent is comprised of with weight ratio 1:1 sodium hydrogen phosphate and sodium dihydrogen phosphate; Described cosolvent is ethanol; Described antioxidant is Butylated hydroxyanisole; Described antibacterial is ethylparaben.

(1) according to the weight proportion of raw material, take medical material, clean and take out impurity, be ground into graininess, with extraction by steam distillation volatile oil, by adding described additive A after volatile oil dilution, obtain medicinal liquid;

For preventing and treating a napkin for allergic rhinitis, described napkin comprises carrier material and medicinal liquid described above.Wherein, described carrier material is paper oleo stock; Described medicinal liquid also comprises 1.3 parts of additive Bs, and described additive B comprises 0.7 part of 0.2 part of Percutaneous absorption enhancer, 0.1 part of pH adjusting agent, 0.2 part of cosolvent, 0.1 part, antioxidant and antibacterial; Described Percutaneous absorption enhancer is Oleum menthae; The mixture that described pH adjusting agent is comprised of with weight ratio 1:1 boric acid and Borax; Described cosolvent is ethanol; Described antioxidant is Butylated hydroxyanisole; Described antibacterial is ethylparaben.

(1) according to the weight proportion of raw material, take medical material, clean and take out impurity, be ground into graininess, with extraction by steam distillation volatile oil, by adding described additive B after volatile oil dilution, obtain medicinal liquid;

(2) above-mentioned medicinal liquid is joined in paper oleo stock, through papermaking processing, obtain described for preventing and treating the napkin of allergic rhinitis.

Embodiment 3

The difference of the present embodiment and above-described embodiment 1 is: described medicinal liquid comprises the extracting solution of the raw material of following weight portion: 25 parts of 50 parts of Flos Magnoliaes, 25 parts of Herba Centipedae and Fructus Xanthii.

For preventing and treating a wet tissue for allergic rhinitis, described wet tissue comprises carrier material and medicinal liquid described above.Wherein, described carrier material is non-woven fabrics; Described medicinal liquid also comprises 1.5 parts of additive A, and described additive A comprises 0.6 part of 0.1 part of osmotic pressure regulator, 0.2 part of wetting agent, 0.1 part of Percutaneous absorption enhancer, 0.2 part of pH adjusting agent, 0.1 part of cosolvent, 0.2 part, antioxidant and antibacterial; Described osmotic pressure regulator is sodium acetate; Described wetting agent is sorbitol; Described Percutaneous absorption enhancer is Polyethylene Glycol; The mixture that described pH adjusting agent is comprised of with weight ratio 1:1.2 sodium hydrogen phosphate and sodium dihydrogen phosphate; Described cosolvent is propylene glycol; Described antioxidant is butylated hydroxyanisol; Described antibacterial is propyl p-hydroxybenzoate.

(1) according to the weight proportion of raw material, take medical material, clean and take out impurity, be ground into powder, with 8 times of amount 95% alcohol reflux 2 times, each 1.5h, extracting solution is concentrated, in concentrated solution, add described additive A, obtain medicinal liquid;

For preventing and treating a napkin for allergic rhinitis, described napkin comprises carrier material and medicinal liquid described above.Wherein, described carrier material is fibrous paper; Described medicinal liquid also comprises 1.5 parts of additive Bs, and described additive B comprises 0.7 part of 0.2 part of Percutaneous absorption enhancer, 0.2 part of pH adjusting agent, 0.2 part of cosolvent, 0.2 part, antioxidant and antibacterial; Described Percutaneous absorption enhancer is carbamide; The mixture that described pH adjusting agent is comprised of with weight ratio 1.2:1 boric acid and Borax; Described cosolvent is propylene glycol; Described antioxidant is butylated hydroxyanisol; Described antibacterial is propyl p-hydroxybenzoate.

(1) according to the weight proportion of raw material, take medical material, clean and take out impurity, be ground into the powder of particle diameter < 1mm, use supercritical carbon dioxide extraction apparatus carbon dioxide abstraction quintessence oil, extraction conditions is: extracting pressure 15MPa, 35 ℃ of extraction temperature, extraction time 70min, gained quintessence oil dissolve with ethanol, adds described additive B after dilute with water, obtain medicinal liquid;

Embodiment 4

The difference of the present embodiment and above-described embodiment 1 is: described medicinal liquid comprises the extracting solution of the raw material of following weight portion: 35 parts of 70 parts of Flos Magnoliaes, 35 parts of Herba Centipedae and Fructus Xanthii.

For preventing and treating a wet tissue for allergic rhinitis, described wet tissue comprises carrier material and medicinal liquid described above.Wherein, described carrier material is non-woven fabrics; Described medicinal liquid also comprises 1.7 parts of additive A, and described additive A comprises 0.6 part of 0.2 part, surfactant, 0.1 part of osmotic pressure regulator, 0.2 part of wetting agent, 0.1 part of Percutaneous absorption enhancer, 0.2 part of pH adjusting agent, 0.1 part of cosolvent, 0.2 part, antioxidant and antibacterial; Described surfactant is Fel Bovis seu Bubali sodium sulfonate; Described osmotic pressure regulator is glucose; Described wetting agent is liquid paraffin; Described Percutaneous absorption enhancer is carbamide; The mixture that described pH adjusting agent is comprised of with weight ratio 1:0.8 potassium dihydrogen phosphate and dipotassium hydrogen phosphate; Described cosolvent is Liquid Macrogol; Described antioxidant is ethanolamine; Described antibacterial is butyl p-hydroxybenzoate.

(1) according to the weight proportion of raw material, take medical material, clean and take out impurity, be ground into powder, with 8 times of amount distilled water immersion 1h, heating decocts 3 times, and each 1.5h is concentrated by extracting solution, adds described additive A in concentrated solution, obtains medicinal liquid;

For preventing and treating a napkin for allergic rhinitis, described napkin comprises carrier material and medicinal liquid described above.Wherein, described carrier material is paper oleo stock; Described medicinal liquid also comprises 1.7 parts of additive Bs, and described additive B comprises 0.7 part of 0.2 part of viscosity modifier, 0.2 part of Percutaneous absorption enhancer, 0.2 part of pH adjusting agent, 0.2 part of cosolvent, 0.2 part, antioxidant and antibacterial; Described viscosity modifier is dextran; Described Percutaneous absorption enhancer is Polyethylene Glycol; The mixture that described pH adjusting agent is comprised of with weight ratio 0.8:1 sodium carbonate and sodium bicarbonate; Described cosolvent is Liquid Macrogol; Described antioxidant is ethanolamine; Described antibacterial is butyl p-hydroxybenzoate.

Embodiment 5

The difference of the present embodiment and above-described embodiment 1 is: described medicinal liquid comprises the extracting solution of the raw material of following weight portion: 40 parts of 90 parts of Flos Magnoliaes, 40 parts of Herba Centipedae and Fructus Xanthii.

For preventing and treating a wet tissue for allergic rhinitis, described wet tissue comprises carrier material and medicinal liquid described above.Wherein, described carrier material is non-woven fabrics; Described medicinal liquid also comprises 2 parts of additive A, and described additive A comprises 0.7 part of 0.2 part, surfactant, 0.2 part of osmotic pressure regulator, 0.2 part of wetting agent, 0.1 part of Percutaneous absorption enhancer, 0.2 part of pH adjusting agent, 0.2 part of cosolvent, 0.2 part, antioxidant and antibacterial; Described surfactant is benzyl chloride methyl ethylamine; Described osmotic pressure regulator is sodium chloride; Described wetting agent is hyaluronic acid; Described Percutaneous absorption enhancer is Oleum menthae; The mixture that described pH adjusting agent is comprised of with weight ratio 1:1 potassium dihydrogen phosphate and dipotassium hydrogen phosphate; Described cosolvent is ethylene glycol 400; Described antioxidant is diethanolamine; Described antibacterial is benzyl alcohol.

(1) according to the weight proportion of raw material, take medical material, clean and take out impurity, be ground into the powder of particle diameter < 1mm, use supercritical carbon dioxide extraction apparatus carbon dioxide abstraction quintessence oil, extraction conditions is: extracting pressure 20MPa, 40 ℃ of extraction temperature, extraction time 60min, gained quintessence oil dissolve with ethanol, adds described additive A after dilute with water, obtain medicinal liquid;

For preventing and treating a napkin for allergic rhinitis, described napkin comprises carrier material and medicinal liquid described above.Wherein, described carrier material is fibrous paper; Described medicinal liquid also comprises 2 parts of additive Bs, and described additive B comprises 0.6 part of 0.3 part of viscosity modifier, 0.2 part of Percutaneous absorption enhancer, 0.2 part of pH adjusting agent, 0.4 part of cosolvent, 0.3 part, antioxidant and antibacterial; Described viscosity modifier is hyaluronic acid sodium; Described Percutaneous absorption enhancer is azone; The mixture that described pH adjusting agent is comprised of with weight ratio 1:1 potassium dihydrogen phosphate and dipotassium hydrogen phosphate; Described cosolvent is ethylene glycol 400; Described antioxidant is diethanolamine; Described antibacterial is benzyl alcohol.

(1) according to the weight proportion of raw material, take medical material, clean and take out impurity, be ground into the powder of particle diameter < 1mm, use supercritical carbon dioxide extraction apparatus carbon dioxide abstraction quintessence oil, extraction conditions is: extracting pressure 20MPa, 40 ℃ of extraction temperature, extraction time 60min, gained quintessence oil dissolve with ethanol, adds described additive B, obtains medicinal liquid;

Embodiment 6

The difference of the present embodiment and above-described embodiment 1 is: described medicinal liquid also comprises the extracting solution of 5 parts of 5 parts of Radixs Stephaniae Tetrandrae, 5 parts of the Fructus Kochiae, 5 parts of Flos Chrysanthemi Indicis and Rhizoma Chuanxiongs.

Described additive A comprises 0.55 part of 0.1 part, surfactant, 0.05 part of osmotic pressure regulator, 0.1 part of wetting agent, 0.05 part of Percutaneous absorption enhancer, 0.05 part of pH adjusting agent, 0.05 part of cosolvent, 0.05 part, antioxidant and antibacterial; Described surfactant is dodecylbenzene sodium sulfonate; Described osmotic pressure regulator is potassium chloride; Described wetting agent is sorbitol; Described Percutaneous absorption enhancer is Oleum Terebinthinae; The mixture that described pH adjusting agent is comprised of with weight ratio 1:1.2 potassium dihydrogen phosphate and dipotassium hydrogen phosphate; Described cosolvent is propylene glycol; Described antioxidant is triethanolamine; Described antibacterial is chlorobutanol.

Described additive B comprises 0.55 part of 0.1 part of viscosity modifier, 0.05 part of Percutaneous absorption enhancer, 0.1 part of pH adjusting agent, 0.1 part of cosolvent, 0.1 part, antioxidant and antibacterial; Described viscosity modifier is polyvinyl alcohol; Described Percutaneous absorption enhancer is dimethyl sulfoxide; The mixture that described pH adjusting agent is comprised of with weight ratio 1.2:1 sodium carbonate and sodium bicarbonate; Described cosolvent is glycerol; Described antioxidant is triethanolamine; Described antibacterial is chlorobutanol.

Embodiment 7

The difference of the present embodiment and above-described embodiment 2 is: described medicinal liquid also comprises the extracting solution of 10 parts of 5 parts of Radixs Stephaniae Tetrandrae, 5 parts of the Fructus Kochiae, 5 parts of Flos Chrysanthemi Indicis and Rhizoma Chuanxiongs.

Described additive A comprises 0.6 part of 0.1 part, surfactant, 0.1 part of osmotic pressure regulator, 0.1 part of wetting agent, 0.1 part of Percutaneous absorption enhancer, 0.1 part of pH adjusting agent, 0.1 part of cosolvent, 0.1 part, antioxidant and antibacterial; Described surfactant is sodium acetate; Described osmotic pressure regulator is sodium chloride; Described wetting agent is liquid paraffin; Described Percutaneous absorption enhancer is dimethyl sulfoxide; The mixture that described pH adjusting agent is comprised of with weight ratio 1:0.8 potassium carbonate and potassium bicarbonate; Described cosolvent is ethanol; Described antioxidant is cholesterol; Described antibacterial is Oleum menthae.

Described additive B comprises 0.6 part of 0.1 part of viscosity modifier, 0.2 part of Percutaneous absorption enhancer, 0.1 part of pH adjusting agent, 0.1 part of cosolvent, 0.2 part, antioxidant and antibacterial; Described viscosity modifier is CP; Described Percutaneous absorption enhancer is dimethyl sulfoxide; The mixture that described pH adjusting agent is comprised of with weight ratio 0.8:1 acetic acid and sodium acetate; Described cosolvent is Liquid Macrogol; Described antioxidant is cholesteryl ester; Described antibacterial is Oleum Asari.

Embodiment 8

The difference of the present embodiment and above-described embodiment 3 is: described medicinal liquid also comprises the extracting solution of 20 parts of 10 parts of Radixs Stephaniae Tetrandrae, 10 parts of the Fructus Kochiae, 10 parts of Flos Chrysanthemi Indicis and Rhizoma Chuanxiongs.

Described additive A comprises 0.7 part of 0.1 part of osmotic pressure regulator, 0.1 part of wetting agent, 0.1 part of Percutaneous absorption enhancer, 0.2 part of pH adjusting agent, 0.1 part of cosolvent, 0.1 part of suspending agent, 0.1 part, antioxidant and antibacterial; Described osmotic pressure regulator is hexadecanol sodium sulfate; Described wetting agent is hyaluronic acid; Described Percutaneous absorption enhancer is azone; The mixture that described pH adjusting agent is comprised of with weight ratio 1:1 potassium carbonate and potassium bicarbonate; Described cosolvent is PEG400; Described suspending agent is arabic gum; Described antioxidant is sodium sulfite; Described antibacterial is phenoxyethanol.

Described additive B comprises 0.7 part of 0.1 part of Percutaneous absorption enhancer, 0.2 part of pH adjusting agent, 0.1 part of cosolvent, 0.2 part of suspending agent, 0.2 part, antioxidant and antibacterial; Described Percutaneous absorption enhancer is azone; The mixture that described pH adjusting agent is comprised of with weight ratio 1:1 acetic acid and sodium acetate; Described cosolvent is glycerol; Described suspending agent is polyvinylpyrrolidone; Described antioxidant is sodium sulfite; Described antibacterial is benzalkonium bromide.

Embodiment 9

The difference of the present embodiment and above-described embodiment 4 is: described medicinal liquid also comprises the extracting solution of 30 parts of 20 parts of Radixs Stephaniae Tetrandrae, 20 parts of the Fructus Kochiae, 20 parts of Flos Chrysanthemi Indicis and Rhizoma Chuanxiongs.

Described additive A comprises 0.7 part of 0.1 part of osmotic pressure regulator, 0.2 part of wetting agent, 0.1 part of Percutaneous absorption enhancer, 0.2 part of pH adjusting agent, 0.1 part of cosolvent, 0.2 part of suspending agent, 0.1 part, antioxidant and antibacterial; Described osmotic pressure regulator is potassium chloride; Described wetting agent is sorbitol; Described Percutaneous absorption enhancer is Polyethylene Glycol; The mixture that described pH adjusting agent is comprised of with weight ratio 1:1.2 potassium carbonate and potassium bicarbonate; Described cosolvent is Liquid Macrogol; Described suspending agent is tragakanta; Described antioxidant is sodium pyrosulfite; Described antibacterial is Bian rope chloramines.

Described additive B comprises 0.7 part of 0.2 part of Percutaneous absorption enhancer, 0.2 part of pH adjusting agent, 0.2 part of cosolvent, 0.2 part of suspending agent, 0.2 part, antioxidant and antibacterial; Described Percutaneous absorption enhancer is Polyethylene Glycol; The mixture that described pH adjusting agent is comprised of with weight ratio 1.2:1 acetic acid and sodium acetate; Described cosolvent is propylene glycol; Described suspending agent is methylcellulose; Described antioxidant is sodium nitrite; Described antibacterial is benzalkonium chloride.

Embodiment 10

The difference of the present embodiment and above-described embodiment 5 is: described medicinal liquid also comprises the extracting solution of 30 parts of 30 parts of Radixs Stephaniae Tetrandrae, 30 parts of the Fructus Kochiae, 30 parts of Flos Chrysanthemi Indicis and Rhizoma Chuanxiongs.

Described additive A comprises 0.7 part of 0.2 part of osmotic pressure regulator, 0.2 part of wetting agent, 0.2 part of Percutaneous absorption enhancer, 0.1 part of pH adjusting agent, 0.2 part of cosolvent, 0.2 part of suspending agent, 0.2 part, antioxidant and antibacterial; Described osmotic pressure regulator is sodium acetate; Described wetting agent is liquid paraffin; Described Percutaneous absorption enhancer is carbamide; The mixture that described pH adjusting agent is comprised of with weight ratio 1:0.8 citric acid and sodium citrate; Described cosolvent is ethanol; Described suspending agent is arabic gum; Described antioxidant is sodium thiosulfate; Described antibacterial is cetrimonium bromide.

Described additive B comprises 0.7 part of 0.3 part of Percutaneous absorption enhancer, 0.2 part of pH adjusting agent, 0.3 part of cosolvent, 0.2 part of suspending agent, 0.3 part, antioxidant and antibacterial; Described Percutaneous absorption enhancer is carbamide; The mixture that described pH adjusting agent is comprised of with weight ratio 0.8:1 tartaric acid and sodium tartrate; Described cosolvent is glycerol; Described suspending agent is tragakanta; Described antioxidant is ascorbic acid; Described antibacterial is polyhexamethylene guanidine.

Embodiment 11

The difference of the present embodiment and above-described embodiment 6 is: described medicinal liquid also comprises the extracting solution of 10 parts of 5 parts of Flos Camelliae Japonicae, 10 parts of Cortex toonae sinensis radicis, 4 parts of Bai Mang and Flos Impatientiss.

Described additive A comprises 0.55 part of 0.1 part of osmotic pressure regulator, 0.05 part of wetting agent, 0.05 part of Percutaneous absorption enhancer, 0.1 part of pH adjusting agent, 0.05 part of cosolvent, 0.05 part of suspending agent, 0.05 part, antioxidant and antibacterial; Described osmotic pressure regulator is glucose; Described wetting agent is hyaluronic acid; Described Percutaneous absorption enhancer is Oleum menthae; The mixture that described pH adjusting agent is comprised of with weight ratio 1:1 citric acid and sodium citrate; The mixture that described cosolvent is comprised of with weight ratio 1.4:1 glycerol and propylene glycol; Described suspending agent is polyvinylpyrrolidone; Described antioxidant is ascorbyl stearate; Described antibacterial is Chlorhexidine hydrochloride.

Described additive B comprises 0.55 part of 0.1 part of Percutaneous absorption enhancer, 0.05 part of pH adjusting agent, 0.1 part of cosolvent, 0.1 part of suspending agent, 0.1 part, antioxidant and antibacterial; Described Percutaneous absorption enhancer is Oleum menthae; The mixture that described pH adjusting agent is comprised of with weight ratio 1:1 tartaric acid and sodium tartrate; The mixture that described cosolvent is comprised of with weight ratio 1.8:1 glycerol and propylene glycol; Described suspending agent is hydroxy methocel; Described antioxidant is cysteine; Described antibacterial is chlorhexidine acetate.

Embodiment 12

The difference of the present embodiment and above-described embodiment 7 is: described medicinal liquid also comprises the extracting solution of 12 parts of 7 parts of Flos Camelliae Japonicae, 12 parts of Cortex toonae sinensis radicis, 6 parts of Bai Mang and Flos Impatientiss.

Described additive A comprises 0.6 part of 0.1 part, surfactant, 0.1 part of osmotic pressure regulator, 0.1 part of wetting agent, 0.05 part of Percutaneous absorption enhancer, 0.1 part of pH adjusting agent, 0.1 part of cosolvent, 0.1 part of suspending agent, 0.05 part, antioxidant and antibacterial; Described surfactant is sodium lauryl sulphate; Described osmotic pressure regulator is glucose; Described wetting agent is sorbitol; Described Percutaneous absorption enhancer is Oleum Terebinthinae; The mixture that described pH adjusting agent is comprised of with weight ratio 1:1.2 citric acid and sodium citrate; The mixture that described cosolvent is comprised of with weight ratio 1.6:1 glycerol and propylene glycol; Described suspending agent is hydroxy methocel; Described antioxidant is tocopherol acetas; Described antibacterial is ethyl hydroxybenzoate.

Described additive B comprises 0.6 part of 0.1 part of viscosity modifier, 0.1 part of Percutaneous absorption enhancer, 0.2 part of pH adjusting agent, 0.1 part of cosolvent, 0.1 part of suspending agent, 0.1 part, antioxidant and antibacterial; Described viscosity modifier is chitosan; Described Percutaneous absorption enhancer is Oleum Terebinthinae; The mixture that described pH adjusting agent is comprised of with weight ratio 1.2:1 tartaric acid and sodium tartrate; The mixture that described cosolvent is comprised of with weight ratio 1.6:1 glycerol and propylene glycol; Described suspending agent is polyvinylpyrrolidone; Described antioxidant is disodiumedetate; Described antibacterial is poly hexamethylene biguanide.

Embodiment 13

The difference of the present embodiment and above-described embodiment 8 is: described medicinal liquid also comprises the extracting solution of 14 parts of 10 parts of Flos Camelliae Japonicae, 15 parts of Cortex toonae sinensis radicis, 8 parts of Bai Mang and Flos Impatientiss.

Described additive A comprises 0.6 part of 0.1 part, surfactant, 0.1 part of osmotic pressure regulator, 0.2 part of wetting agent, 0.1 part of Percutaneous absorption enhancer, 0.1 part of pH adjusting agent, 0.1 part of cosolvent, 0.1 part of suspending agent, 0.1 part, antioxidant and antibacterial; The mixture that described surfactant is comprised of with weight ratio 1:2:1.5 Fel Bovis seu Bubali sodium sulfonate, benzyl chloride methyl ethylamine and polyoxyethylene hydrogenated Oleum Ricini; The mixture that described osmotic pressure regulator is comprised of with weight ratio 2:1 sodium chloride and glucose; The mixture that described wetting agent is comprised of with weight ratio 1.2:1:1.4 liquid paraffin, hyaluronic acid and sorbitol; The mixture that described Percutaneous absorption enhancer is comprised of with weight ratio 1.2:1 azone and Oleum menthae; The mixture that described pH adjusting agent is comprised of with weight ratio 1:0.8 sodium hydrogen phosphate and sodium dihydrogen phosphate; The mixture that described cosolvent is comprised of with weight ratio 1.8:1 glycerol and propylene glycol; The mixture that described suspending agent is comprised of with weight ratio 1:1.5 polyvinylpyrrolidone and hydroxy methocel; The mixture that described antioxidant is comprised of with weight ratio 2:1 sodium sulfite and ascorbic acid; The mixture that described antibacterial is comprised of with weight ratio 0.4:1.2:1 ethylparaben, chlorobutanol and Oleum Asari.

Described additive B comprises 0.6 part of 0.1 part of viscosity modifier, 0.2 part of Percutaneous absorption enhancer, 0.1 part of pH adjusting agent, 0.2 part of cosolvent, 0.1 part of suspending agent, 0.2 part, antioxidant and antibacterial; The mixture that described viscosity modifier is comprised of with weight ratio 1:1.8:2.5 hyaluronic acid sodium, polyvinyl alcohol and CP; The mixture that described Percutaneous absorption enhancer is comprised of with weight ratio 1:1.6 azone and Oleum Terebinthinae; The mixture that described pH adjusting agent is comprised of with weight ratio 0.8:1 boric acid and Borax; The mixture that described cosolvent is comprised of with weight ratio 1.4:1 glycerol and propylene glycol; The mixture that described suspending agent is comprised of with weight ratio 1:1.5 polyvinylpyrrolidone and methylcellulose; The mixture that described antioxidant is comprised of with weight ratio 1.2:1 sodium pyrosulfite and ascorbic acid; The mixture that described antibacterial is comprised of with weight ratio 0.8:1.6:1 methyl parahydroxybenzoate, chlorobutanol and Oleum menthae.

Embodiment 14

The difference of the present embodiment and above-described embodiment 9 is: described medicinal liquid also comprises the extracting solution of 16 parts of 12 parts of Flos Camelliae Japonicae, 17 parts of Cortex toonae sinensis radicis, 10 parts of Bai Mang and Flos Impatientiss.

Described additive A comprises 0.6 part of 0.1 part, surfactant, 0.1 part of osmotic pressure regulator, 0.2 part of wetting agent, 0.1 part of Percutaneous absorption enhancer, 0.2 part of pH adjusting agent, 0.1 part of cosolvent, 0.1 part of suspending agent, 0.2 part, antioxidant and antibacterial; The mixture that described surfactant is comprised of with weight ratio 1:2.5:2 Fel Bovis seu Bubali sodium sulfonate, benzyl chloride methyl ethylamine and polyoxyethylene hydrogenated Oleum Ricini; The mixture that described osmotic pressure regulator is comprised of with weight ratio 3:1 sodium chloride and glucose; The mixture that described wetting agent is comprised of with weight ratio 1.5:1:1.8 liquid paraffin, hyaluronic acid and sorbitol; The mixture that described Percutaneous absorption enhancer is comprised of with weight ratio 1.5:1 azone and Oleum menthae; The mixture that described pH adjusting agent is comprised of with weight ratio 1:1 sodium hydrogen phosphate and sodium dihydrogen phosphate; The mixture that described cosolvent is comprised of with weight ratio 1.4:1 glycerol and propylene glycol; The mixture that described suspending agent is comprised of with weight ratio 1:2 polyvinylpyrrolidone and hydroxy methocel; The mixture that described antioxidant is comprised of with weight ratio 2.5:1 sodium sulfite and ascorbic acid; The mixture that described antibacterial is comprised of with weight ratio 0.6:1.4:1 ethylparaben, chlorobutanol and Oleum Asari.

Described additive B comprises 0.7 part of 0.2 part of viscosity modifier, 0.2 part of Percutaneous absorption enhancer, 0.1 part of pH adjusting agent, 0.2 part of cosolvent, 0.1 part of suspending agent, 0.2 part, antioxidant and antibacterial; The mixture that described viscosity modifier is comprised of with weight ratio 1:2.1:3 hyaluronic acid sodium, polyvinyl alcohol and CP; The mixture that described Percutaneous absorption enhancer is comprised of with weight ratio 1:2 azone and Oleum Terebinthinae; The mixture that described pH adjusting agent is comprised of with weight ratio 1:1 boric acid and Borax; The mixture that described cosolvent is comprised of with weight ratio 1.6:1 glycerol and propylene glycol; The mixture that described suspending agent is comprised of with weight ratio 1:2 polyvinylpyrrolidone and hydroxy methocel; The mixture that described antioxidant is comprised of with weight ratio 1.5:1 sodium pyrosulfite and ascorbic acid; The mixture that described antibacterial is comprised of with weight ratio 1:2:1 methyl parahydroxybenzoate, chlorobutanol and Oleum menthae.

Embodiment 15

The difference of the present embodiment and above-described embodiment 10 is: described medicinal liquid also comprises the extracting solution of 18 parts of 15 parts of Flos Camelliae Japonicae, 20 parts of Cortex toonae sinensis radicis, 12 parts of Bai Mang and Flos Impatientiss.

Described additive A comprises 0.7 part of 0.2 part, surfactant, 0.1 part of osmotic pressure regulator, 0.2 part of wetting agent, 0.1 part of Percutaneous absorption enhancer, 0.2 part of pH adjusting agent, 0.2 part of cosolvent, 0.2 part of suspending agent, 0.1 part, antioxidant and antibacterial; The mixture that described surfactant is comprised of with weight ratio 1:3:2.5 Fel Bovis seu Bubali sodium sulfonate, benzyl chloride methyl ethylamine and polyoxyethylene hydrogenated Oleum Ricini; The mixture that described osmotic pressure regulator is comprised of with weight ratio 4:1 sodium chloride and glucose; The mixture that described wetting agent is comprised of with weight ratio 1.8:1:2.2 liquid paraffin, hyaluronic acid and sorbitol; The mixture that described Percutaneous absorption enhancer is comprised of with weight ratio 1.8:1 azone and Oleum menthae; The mixture that described pH adjusting agent is comprised of with weight ratio 1:1.2 sodium hydrogen phosphate and sodium dihydrogen phosphate; The mixture that described cosolvent is comprised of with weight ratio 1.6:1 glycerol and propylene glycol; The mixture that described suspending agent is comprised of with weight ratio 1:2.5 polyvinylpyrrolidone and hydroxy methocel; The mixture that described antioxidant is comprised of with weight ratio 3:1 sodium sulfite and ascorbic acid; The mixture that described antibacterial is comprised of with weight ratio 0.8:1.6:1 ethylparaben, chlorobutanol and Oleum Asari.

Described additive B comprises 0.7 part of 0.2 part of viscosity modifier, 0.2 part of Percutaneous absorption enhancer, 0.2 part of pH adjusting agent, 0.2 part of cosolvent, 0.3 part of suspending agent, 0.2 part, antioxidant and antibacterial; The mixture that described viscosity modifier is comprised of with weight ratio 1:2.4:3.5 hyaluronic acid sodium, polyvinyl alcohol and CP; The mixture that described Percutaneous absorption enhancer is comprised of with weight ratio 1:2.4 azone and Oleum Terebinthinae; The mixture that described pH adjusting agent is comprised of with weight ratio 1.2:1 boric acid and Borax; The mixture that described cosolvent is comprised of with weight ratio 1.4:1 glycerol and propylene glycol; The mixture that described suspending agent is comprised of with weight ratio 1:2.5 polyvinylpyrrolidone and hydroxy methocel; The mixture that described antioxidant is comprised of with weight ratio 1.8:1 sodium pyrosulfite and ascorbic acid; The mixture that described antibacterial is comprised of with weight ratio 1.2:2.4:1 methyl parahydroxybenzoate, chlorobutanol and Oleum menthae.

One, the wet tissue clinical trial of embodiment 1-15

1. test objective

Get the prepared wet tissue of embodiment 1-15 and carry out clinical trial, observe clinical efficacy.Effectiveness and reliability is evaluated.

2. EXPERIMENTAL DESIGN

Employing is random, parallel control carries out clinical research (the commercially available common clean wet tissue of take is contrast); Test case adds up to 384 examples, is divided into 16 groups, every group of 24 examples.

3. test grouping

(1) 1-15 of seminar: the wet tissue of preparing by embodiment 1-15.

(2) matched group: commercially available common clean wet tissue.

Exclusion standard: nose malignant tumor; Gestation and purpose gestation or women breast-feeding their children; Allergic constitution person or those who are allergic to this drug; Merge the serious primary disease such as cardiovascular, liver, kidney, brain and hemopoietic system, psychotic; Within nearly 2 weeks, used other associated treatment medicines person.

Inclusion criteria: age 18-65 year; Male or female; Meet the doctor trained in Western medicine of allergic rhinitis, acute rhinitis, chronic rhinitis and sinusitis and the patient of TCM syndrome diagnostic criteria (wherein allergic rhinitis 384 examples).Allergic rhinitis: with reference to otolaryngology branch of Chinese Medical Association, clinical diagnosis is carried out in the allergic rhinitis diagnostic criteria (1997, Haikou) that hals,Nasen und Ohrenheilkunde magazine editorial board of Chinese Medical Association works out.On age, the course of disease, sick kind, severity extent relatively, through statistical procedures, there was no significant difference, has comparability (P > 0.05) to each group.

4. usage and dosage: seminar is identical with matched group usage, is all to wipe nose every day 6 times 4 weeks courses for the treatment of.Each wiping nose time is 1-2min, wipes nose and rubs pressure wing of nose both sides simultaneously, and coordinate deep breathing.

5. clinical efficacy standard:

(1) effective: nasal obstruction, rhinocnesmus, sneeze, rhinorrhea, olfactory disorder, headache, giddy, the subjective symptoms such as weak disappear, local tenderness or red and swollen disappearance, nasal mucosa is congested, swelling disappears, and without purulent secretion, generates.

(2) effective: subjective symptoms disappears substantially, and purulent secretion obviously reduces.

(3) invalid: subjective symptoms and inspection are all not improved.

6. safety observation:

(1) blood, routine urianlysis; (2) heart, liver (ALT, AST), kidney (BUN, Cr) functional check; Above index in treatment each observational record of front and back once.(3) observed and recorded adverse events in whole process of the test, carries out record, report and the processing to patient of Adverse Event.

7. result of the test

Clinical test results is in Table 1, the curative effect of the 1-15 of seminar respectively with matched group comparison, all apparently higher than matched group, difference has statistical significance (P < 0.05).

Table 1 clinical test results

Seminar and matched group 1-15 are on blood, urine, just routine and electrocardiogram, without impact, without toxicity, in Clinical observation process, have no any untoward reaction to liver, renal function.

8. conclusion (of pressure testing)

Wet tissue of the present invention has good curative effect to rhinitis, is significantly better than common Clean-wet tissue, and has good safety and compliance.Wet tissue of the present invention can clean nose and facial in; the Chinese medicine extraction liquid containing in wet tissue and volatile ingredient can absorb by contact skin and nasal membrane; thereby the effect that plays prevention and the outbreak of alleviation allergic rhinitis, chronic conditioning, protection nasal membrane is the good succedaneum of Allergic Rhinitis and normal person's routine use wet tissue.

Two, the napkin clinical trial of embodiment 1-15

1. experiment purposes of this clinical trial, 2. experimental design, 3. experiment grouping, 4. usage and dosage, 5. clinical efficacy standard, 6. safety observation is all consistent with the clinical trial of above-mentioned wet tissue, just changes wet tissue into napkin, do not repeat them here.

7. result of the test

Clinical test results is in Table 2, the curative effect of the 1-15 of seminar respectively with matched group comparison, all apparently higher than matched group, difference has statistical significance (P < 0.05).

Table 1 clinical test results

Seminar and matched group are on blood, urine, just routine and electrocardiogram, without impact, without toxicity, in Clinical observation process, have no any untoward reaction to liver, renal function.

8. conclusion (of pressure testing)

Napkin of the present invention has good curative effect to rhinitis, is significantly better than common Clean-wet tissue, and has good safety and compliance.Napkin of the present invention can clean nose and facial in; the Chinese medicine volatile ingredient containing in napkin can absorb by contact skin and nasal membrane; thereby the effect that plays prevention and the outbreak of alleviation allergic rhinitis, chronic conditioning, protection nasal membrane is the good succedaneum of Allergic Rhinitis and normal person's routine use napkin.

Above-described embodiment is preferably implementation of the present invention, and in addition, the present invention can also realize by alternate manner, and any apparent replacement is all within protection scope of the present invention without departing from the inventive concept of the premise.

Claims

1. for preventing and treating the medicinal liquid of allergic rhinitis, it is characterized in that: described medicinal liquid comprises the extracting solution of the raw material of following weight portion: Flos Magnoliae 10-90 part, Herba Centipedae 5-40 part and Fructus Xanthii 5-40 part.

2. according to claim 1 for preventing and treating the medicinal liquid of allergic rhinitis, it is characterized in that: described medicinal liquid also comprises the extracting solution of Radix Stephaniae Tetrandrae 5-30 part, Fructus Kochiae 5-30 part, Flos Chrysanthemi Indici 5-30 part and Rhizoma Chuanxiong 5-30 part.

3. according to claim 2 for preventing and treating the medicinal liquid of allergic rhinitis, it is characterized in that: described medicinal liquid also comprises Flos Camelliae Japonicae 5-15 part, Cortex toonae sinensis radicis 10-20 part, Bai Mang 4-12 part and Flos Impatientis 10-18 part.

Application rights require that medicinal liquid described in 1-3 any one makes for preventing and treating a wet tissue for allergic rhinitis, it is characterized in that: described wet tissue comprises carrier material and described medicinal liquid.

5. according to claim 4 a kind of for preventing and treating the wet tissue of allergic rhinitis, it is characterized in that: described carrier material is non-woven fabrics; Described medicinal liquid also comprises additive A 1-2 part, and described additive A comprises at least one in surfactant, osmotic pressure regulator, wetting agent, Percutaneous absorption enhancer, pH adjusting agent, cosolvent, suspending agent, antioxidant and antibacterial.

6. a kind of for preventing and treating the preparation method of the wet tissue of allergic rhinitis as described in claim 5 any one, is characterized in that: comprise the steps:

(1) according to the weight proportion of raw material, take medical material, pulverize or grind, after extraction, add described additive A, obtain medicinal liquid;

Application rights require that medicinal liquid described in 1-3 any one makes for preventing and treating a napkin for allergic rhinitis, it is characterized in that: described napkin comprises carrier material and described medicinal liquid.

8. according to claim 7 a kind of for preventing and treating the napkin of allergic rhinitis, it is characterized in that: described carrier material is fibrous paper or paper oleo stock; Described medicinal liquid also comprises additive B 1-2 part, and described additive B comprises at least one in viscosity modifier, Percutaneous absorption enhancer, pH adjusting agent, cosolvent, suspending agent, antioxidant and antibacterial.

9. as claimed in claim 8 a kind of for preventing and treating the preparation method of the napkin of allergic rhinitis, it is characterized in that: comprise the steps:

(1) according to the weight proportion of raw material, take medical material, pulverize or grind, after extraction, add described additive B, obtain medicinal liquid;

10. as claimed in claim 8 a kind of for preventing and treating the preparation method of the napkin of allergic rhinitis, it is characterized in that: comprise the steps: